Foresee Pharmaceuticals (6576) reported revenue of NT$125.1 million for Oct 2026, +397.5% year on year and +1,895.4% from the previous month. Revenue for Jan–Oct 2026 was NT$450.4 million (+11.4% year on year).
In Oct 2026, it ranked No. 64 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$125.1 million | +397.5% | +1,895.4% |
| Sep 2026 | NT$6.3 million | -1.1% | -76.5% |
| Aug 2026 | NT$26.7 million | -81.1% | -11.7% |
| Jul 2026 | NT$30.3 million | +242.1% | +176.7% |
| Jun 2026 | NT$10.9 million | -71.8% | -90.8% |
| May 2026 | NT$118.5 million | +749.6% | +126.9% |
| Apr 2026 | NT$52.2 million | -11.2% | +29.1% |
| Mar 2026 | NT$40.4 million | +42.5% | +49.3% |
| Feb 2026 | NT$27.1 million | -61.8% | +111.7% |
| Jan 2026 | NT$12.8 million | +14.8% | -9.3% |
| Dec 2025 | NT$14.1 million | -6.5% | +8.9% |
| Nov 2025 | NT$13 million | +34.3% | -48.5% |
| Oct 2025 | NT$25.2 million | -78.3% | +296.7% |
| Sep 2025 | NT$6.3 million | -74.9% | -95.5% |
| Aug 2025 | NT$141.8 million | +640.8% | +1,501.6% |
| Jul 2025 | NT$8.9 million | -75.2% | -77.2% |
| Jun 2025 | NT$38.9 million | +22.4% | +178.7% |
| May 2025 | NT$13.9 million | +10.9% | -76.3% |
| Apr 2025 | NT$58.8 million | +18.0% | +107.3% |
| Mar 2025 | NT$28.4 million | -33.2% | -60.0% |
| Feb 2025 | NT$70.9 million | +148.3% | +536.9% |
| Jan 2025 | NT$11.1 million | -66.0% | -26.2% |
| Dec 2024 | NT$15.1 million | -47.5% | +56.5% |
| Nov 2024 | NT$9.6 million | -64.2% | -91.7% |
| Oct 2024 | NT$115.8 million | +810.2% | +358.4% |
Jan–Oct 2026 cumulative: NT$450.4 million (+11.4% YoY)
Other Biotech & Medical companies
Compare with peers: Foresee Pharmaceuticals vs PEC / Foresee Pharmaceuticals vs Lotus Pharm / Foresee Pharmaceuticals vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
本月營收較去年同期增加,係因本期認列新劑型新藥Camcevi授權開發里程金收入,去年同期並無所致。
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16